Preclinical development of novel ERRalpha inhibitors for treatment of Triple Negative Breast Cancer. The PREVAIL project will deliver a first-in-class targeted therapeutic for treatment of triple negative breast cancer (TNBC).
SEAL OF EXCELLENCE
Next generation of targeted dendritc cell vaccine for cancer treatment, a therapeutic cancer vaccine technology platform.
We are actively seeking partners in the pharmaceutical industry and clinical centres in order to co-develop our patented vaccine technology.